Infect Chemother.
2022 Jun;54(2):370-371. 10.3947/ic.2022.0045.
Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
- Affiliations
-
- 1Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
- 2Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2531030
- DOI: http://doi.org/10.3947/ic.2022.0045
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
- Erratum: Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
- Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
- The COVID-19 Correspondence Work Experience of Community Health Practitioners
- A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
